Glycogen storage disease type III in Inuit children.

CMAJ

Department of Pediatric Endocrinology, Montreal Children's Hospital, McGill University Health Centre, Montréal, Que.

Published: February 2005

Glycogen storage disease type III (GSD III) was diagnosed in 4 Inuit children (3 confirmed, 1 suspected case) at our institution over the last decade. This rare autosomal recessive disease, which results from a deficiency of the debranching enzyme required for complete degradation of the glycogen molecule, has not been previously described in this population. The possible clinical presentations are heterogeneous, as is the spectrum of severity of this disease. The long-term sequelae can be severe, including recurrent hypoglycemia, hepatic cirrhosis and progressive muscle weakness. These 4 cases would suggest an increased prevalence of GSD III in the Inuit population. Therefore, it is important for health care providers caring for this population to consider and recognize this rare but serious disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC545759PMC
http://dx.doi.org/10.1503/cmaj.1031589DOI Listing

Publication Analysis

Top Keywords

glycogen storage
8
storage disease
8
disease type
8
type iii
8
iii inuit
8
inuit children
8
gsd iii
8
disease
5
iii
4
children glycogen
4

Similar Publications

Current approaches in CRISPR-Cas system for metabolic disorder.

Prog Mol Biol Transl Sci

January 2025

School of Health Sciences & Technology, UPES, Dehradun, Uttarakhand, India. Electronic address:

A new era in genomic medicine has been brought by the development of CRISPR-Cas technology, which presents hitherto unheard-of possibilities for the treatment of metabolic illnesses. The treatment approaches used in CRISPR/Cas9-mediated gene therapy, emphasize distribution techniques such as viral vectors and their use in preclinical models of metabolic diseases like hypercholesterolemia, glycogen storage diseases, and phenylketonuria. The relevance of high-throughput CRISPR screens for target identification in discovering new genes and pathways associated with metabolic dysfunctions is an important aspect of the discovery of new approaches.

View Article and Find Full Text PDF

Starch phosphorylation - A new perspective: A review.

Int J Biol Macromol

January 2025

Biopolymer Analytics, Institute of Biochemistry and Biology, University of Potsdam, Karl-Liebknecht-Str. 24-25, Building 20, Potsdam, Golm, Germany. Electronic address:

The phosphorylation of the storage carbohydrates, starch and glycogen, is a process that is fundamental to their physicochemical properties and their turnover. Therefore, the interest utilising phosphorylation as a biotechnological tool to customize polysaccharides has risen permanently. Today, the phosphoesterification of both carbohydrate forms is much better understood.

View Article and Find Full Text PDF

Background: Late-onset Pompe disease (LOPD) is an autosomal recessive lysosomal storage disorder that results in severe progressive proximal muscle weakness. Over time, reductions in muscle strength result in respiratory failure and a loss of ambulation. Delayed diagnosis of LOPD deprives patients of treatments that can enhance quality of life and potentially slow disease progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!